Signals
Why some “resistant” hypertension isn’t resistant at all, and what cardiology might be missing
A new HCPLive expert discussion highlights growing attention to hypercortisolism as a possible contributor to resistant hypertension and difficult-to-control cardiometabolic disease. Emerging data from MOMENTUM and CATALYST suggest cortisol excess may be more common in these high-risk groups than previously assumed. The policy challenge is not simply whether to screen more patients. It is who…
COVID Vaccines Still Kept Adults Out of Hospital. The Evidence Should Matter.
Gene therapy is entering cardiology. Friedreich ataxia shows why rare heart disease may be the first test
Triglycerides are back in the spotlight. Europe is reviewing Sobi’s olezarsen for severe risk.
When Brain Surgery Is Too Risky, Patients Still Need a Molecular Answer
Germany Is Paying the Price for Leaving Tardive Dyskinesia Behind
A Rare Childhood Ataxia Gets Real Phase III Evidence
Before a TB Vaccine Exists, Africa Is Building the Route to People
Europe’s next stroke bet: can Factor XIa inhibition change prevention without raising bleeding risk?
MASH, a serious fatty liver disease, is becoming a cardiometabolic condition
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.